PHARMAC

We want your feedback on a proposal to fund letermovir, a medicine that helps prevent serious viral infection in people with weak immune systems.

We’d like to hear from patients, whānau, health professionals, advocacy groups, and anyone interested.

🕔 Consultation closes 5pm, Thursday 19 March 2026
📧 Email: [email protected]
🌐 Find out more @

New proposal aims to reduce complications following a stem cell transplant New proposal aims to reduce complications following a stem cell transplant 5 March 2026 Media release Medicines At a glance: Pharmac is proposing to fund letermovir, a medicine that helps prevent cytomegalovirus (CMV) infection, from 1 May 2026. The proposal would mainly benefit people who have had....

📢 Have your say on a new iron treatment proposal

Pharmac is proposing to fund ferric derisomaltose (Monofer) in hospitals from 1 February 2026. This treatment is for people who have experienced low phosphate levels (hypophosphataemia) after other iron infusions.

We want your feedback to help shape this proposal. Consultation closes 5pm, Friday 30 January 2026.

👉 Share your views here:

Proposal to fund ferric derisomaltose in hospitals Proposal to fund ferric derisomaltose in hospitals 20 January 2026 Medicines Consultation Closes 30 Jan What we’re proposing We are proposing to fund ferric derisomaltose (Monofer) in hospitals for people who need an iron infusion and have previously experienced hypophosphataemia after receiving o...

📣 Have your say:

We're proposing to fund a new brand of methylphenidate to help ease ongoing supply issues and provide more treatment options for people with ADHD.

If approved, Rubifen LA would be funded from 1 July 2026.

Consultation is open until 5pm, Thursday 4 December 2025. We want to know what you think.

🔗bit.ly/3X2qHHt

Proposal to fund another new brand of methylphenidate hydrochloride Proposal to fund another new brand of methylphenidate hydrochloride 20 November 2025 Have your say We’re proposing to fund another brand of methylphenidate modified-release: Rubifen LA, supplied by AFT Pharmaceuticals Rubifen LA would be funded from 1 July 2026 for people with attention deficit ...